Heal even the toughest DFUs
with Dermagraft®.
With living fibroblasts to help build granulation tissue and a robust bioabsorbable scaffold, Dermagraft is uniquely bioengineered for DFUs, even in weight-bearing patients.1-7
THE CHALLENGE OF HEALING STALLED DFUs IS REAL—
YET FASTER HEALING IS CRITICAL
Many factors make DFUs challenging to heal. When deciding if your treatment is tough enough for DFUs, you may want to consider these important factors:
Dysfunctional
wound
environment
Patient
comorbidities
Patient
noncompliance
In stalled DFUs, abnormalities with the patient's cells, signaling molecules, and ECM are common.8-14
Comorbid conditions may affect a patient's ability to heal.15,16
In DFUs, adherence to self-care practices is typically low.17
DFUs put patients at risk for serious complications, including amputation.
Every 5 minutes
a lower limb amputation occurs among patients with diabetes18,*
*Based on 2014 US CDC Data.DERMAGRAFT
UNIQUELY DESIGNED FOR TOUGH-TO-TREAT DFUs
With living fibroblasts to help build granulation tissue and a robust bioabsorbable scaffold, Dermagraft is uniquely bioengineered for DFUs, even in weight-bearing patients.1-7
- Dermagraft contains healthy living fibroblasts that proliferate and produce growth factors, collagen, and ECM proteins to help build granulation tissue1-3,6
- DFUs need healthy fibroblasts to help build granulation tissue and accelerate the healing process3,4
- Dermagraft's bioabsorbable scaffold is robust, giving the product its structure and mechanical properties19,20

RELIABLE AND EXTENSIVE EVIDENCE
HEALS MORE DFUs FASTER
HELPS AVOID DFU COMPLICATIONS
64%
Relative increase in %
of patients achieving
complete DFU closure7
PROVEN RESULTS BRING
UNSURPASSED ACCESS
FOR PATIENTS WITH DFUs21
100% of Medicare contractors cover Dermagraft treatment for DFUs
100% of commercial insurance medical policies cover Dermagraft treatment for DFUs
See more about Dermagraft'sunsurpassed insurance coverage

Organogenesis' Circle of Care provides the highest-quality customer service and reimbursement support. Available resources include:
- Benefits verification
- Ordering and shipping information
- Coding details
Want to keep up-to-date on Dermagraft?
Sign up nowPlease refer to the Dermagraft Directions for Use for complete prescribing information.
REFERENCES:
- Dermagraft Directions for Use. Organogenesis Inc; 2015.
- Data on File-016 and -017. Organogenesis Inc.
- Bainbridge P. J Wound Care. 2013; 22(8):407-412.
- Falanga V. Lancet. 2005;366:1736-1743.
- Broughton G, et al. Plast Reconstr Surg. 2006;117(Suppl):12S-34S.
- Roberts C, et al. Can J Plast Surg. 2002;10(Suppl A):6A-13A.
- Marston WA, et al. Diabetes Care. 2003;26(6):1701-1705.
- Barrientos S, et al. Wound Repair Regen. 2008;16:585-601.
- Cook H, et al. J Invest Dermatol. 2000;115:225-233.
- Kim BC, et al. J Cell Physiol. 2003;195:331-336.
- Van de Berg JS, et al. Surg Clin North Am. 2003;83:509-520.
- Mendez MV, et al. J Vasc Surg. 1998;28(26):876-883.
- Wall IB, et al. J Invest Dermatol. 2008;128(10):2526-2540.
- Hunt TK, et al. Adv Skin Wound Care. 2000;13(suppl 2):6-11.
- McEwen LN, et al. J Diabetes Complications. 2013;27(6):588-592.
- Kelly M, et al. Int J Low Extrem Wounds. 2019;18(3):301-308.
- Ploderer B, et al. JMIR Diabetes. 2018;3(4):e10105.
- Centers for Disease Control and Prevention. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed December 12, 2019.
- Conn J, et al. Am J Surg. 1974;128:19-23.
- Munton CGF, et al. Br J Ophthal. 1984;58:941-947.
- Data on file. Organogenesis Inc.